Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JSKN016 and D-0502 in HR+/HER2- Advanced Breast Cancer
NCT07336771Phase 2Not yet recruiting
- Sponsor
- Alphamab Oncology
- Start
- Jan 2026
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of JSKN016 in Hormone-Receptor-Positive Breast Cancer, sponsored by Alphamab Oncology. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
JSKN016
03
Conditions
Hormone-Receptor-Positive Breast Cancer
Beyond the preview
Go deeper on NCT07336771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07336771.